Background: ZTI-01 (fosfomycin for injection) is a novel injectable epoxide antibiotic with a unique mechanism of action by inhibiting MurA at an early step in cell wall synthesis. ZTI-01 as a broad spectrum of activity, including multidrug-resistant pathogens, and is being developed for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP) in the US.
Methods: ZEUS was a multicenter, randomized, double-blind Phase 2/3 trial designed to evaluate the safety and efficacy of ZTI-01 in treatment of hospitalized adults with cUTI or AP versus piperacillin/tazobactam (P-T). The primary endpoint of overall success was defined as clinical cure plus microbiologic eradication in the microbiologic modified intent-to-treat (m-MITT) population at test-of-cure (TOC) visit (Day 19). Patients were randomized to receive 6 g ZTI-01 as 1-hour IV infusion q8h or 4.5 g IV P-T as 1-hour IV infusion q8h for 7 days (up to 14 days if concurrent bacteremia). Clinical cure was defined as complete resolution or significant improvement of signs/symptoms of cUTI or AP present at baseline and no new symptoms, and microbiologic eradication as baseline bacterial pathogen(s) reduced to <10 4 CFU/mL on urine culture and negative on repeat blood culture.
Results:
Of the patients enrolled (N=465), 77.8% had >1 baseline pathogen (m-MITT); the most common baseline pathogens were E. coli (266) and K. pneumoniae (52) . Clinical cure and microbial eradication are presented by pathogen with a frequency of >10 patients with pathogen at baseline (Table 1) . 
Conclusion:
Clinical outcome rates by pathogen at the TOC visit were high and similar for both ZTI-01 and P-T. ZTI-01 is effective in the treatment of cUTI and AP due to Gram-negative uropathogens.
